Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C

Area of Science:

• Hepatology
• Viral Hepatitis Research
• Clinical Trial Analysis

Background:

• Chronic hepatitis C treatment outcomes, particularly sustained viral response, lack validation through clinical events like mortality.
• Patients failing initial therapy are candidates for retreatment, with interferon monotherapy being an option for some.
• The clinical utility and safety of interferon retreatment require rigorous assessment.

Purpose of the Study:

• To evaluate the benefits and harms of interferon monotherapy retreatment in chronic hepatitis C patients.
• To validate surrogate outcomes, such as sustained viral response, against clinical events in this patient group.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials comparing interferon versus placebo or no treatment.
• Searched major databases including Cochrane, MEDLINE, EMBASE, and Science Citation Index Expanded up to August 2012.
• Primary outcomes included mortality, quality of life, and adverse events; secondary outcomes encompassed morbidity, viral response, and histology.

Main Results:

• Seven trials identified; two low-risk bias trials (HALT-C, EPIC3) included 1676 patients with severe fibrosis.
• No significant difference in all-cause or hepatic mortality across all trials; however, low-risk bias trials showed increased all-cause mortality with pegylated interferon.
• Interferon recipients had significantly more sustained viral responses and improved METAVIR scores, but also more adverse events including infections and flu-like symptoms.

Conclusions:

• Interferon retreatment in patients with severe fibrosis showed no significant clinical benefit and potentially increased all-cause mortality.
• While surrogate outcomes like sustained viral response improved, adverse events were more common with interferon retreatment.
• Interferon monotherapy retreatment is not recommended for these patients; sustained viral response requires further validation as a surrogate marker.